Navigation Links
Johnson & Johnson Announces Agreement To Acquire Novira Therapeutics, Inc.
Date:11/4/2015

NEW BRUNSWICK, N.J., Nov. 4, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.  The acquisition includes Novira's portfolio of novel antivirals, including its lead candidate, NVR 3-778.  Financial terms of the transaction have not been disclosed.

NVR 3-778 is a small molecule, direct acting antiviral, for oral administration in patients with HBV that inhibits the HBV core or capsid protein. HBV core is a novel and promising drug target since it is involved in multiple activities required for viral replication and persistence.

"We are excited about the prospect this acquisition offers to accelerate the development of curative treatments for people affected by chronic hepatitis B," said William N. Hait, M.D., Ph.D., Global Head, Research & Development, Janssen Pharmaceutical Companies of Johnson & Johnson. "NVR 3-778 offers the potential for efficient suppression of virus production and replication, which could help address the remaining unmet medical needs."

The closing is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The transaction is expected to close during the fourth quarter of 2015.

"Chronic hepatitis B is a potentially fatal liver disease with approximately 60 percent of hepatocellular carcinoma attributed to infection with the hepatitis B virus," said Lawrence Blatt, PhD Global Head, Infectious Diseases and Vaccines, Janssen and Chief Executive Officer, Alios Biopharma, part of the Janssen Pharmaceutical Companies. "With more than 350 million people affected worldwide we seek to overcome treatment challenges, such as the requirement for people to endure lifelong therapy, through scientific innovation.  Combining Novira's recent breakthroughs with our vast experience in viral diseases we endeavor to deliver novel medicines for patients suffering from this insidious disease." 

About Johnson & Johnson

Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

About Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we are dedicated to addressing some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.  Please visit http://www.janssen.com/ for more information.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the acquisition of Novira Therapeutics, Inc.., and development of NVR 3-778. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and Johnson & Johnson. Risks and uncertainties include, but are not limited to: the satisfaction of closing conditions for the acquisition, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act and certain customary closing conditions; the possibility that the transaction will not be completed or, if completed, not completed in the expected timeframe; the potential that the expected benefits and opportunities may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to regulations and domestic and foreign health care reforms; and general industry conditions, including trends toward health care cost containment. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the operations and clinical work of Novira Therapeutics. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.govwww.jnj.com or on request from Johnson & Johnson. The Janssen Pharmaceutical Companies and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.


'/>"/>
SOURCE Johnson & Johnson
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Johnson & Johnson Announces Start of Clinical Trial of Ebola Vaccine Regimen in Sierra Leone
2. Johnson & Johnson Announces Completion of Cordis Divestiture to Cardinal Health
3. UbiVac Announces Collaboration with Johnson & Johnson Innovation to Develop and Test, in Preclinical Studies, a Vaccine to Intercept Oral Cancer
4. Johnson & Johnsons Ethicon Wants Transvaginal Mesh $1.2MM Verdict Thrown Out, says Legal-Bay Lawsuit Settlement Funding
5. Johnson & Johnson Innovation Announces Collaboration on Immuno-Oncology Antibody ADC-1013 with Alligator Bioscience
6. Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus
7. Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
8. PDA Announces Support for the Johnson & Johnson Kilmer Conference
9. Johnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed $1 Billion in Revenue
10. Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines
11. PDA Extends Richard M. Johnson as President/CEO for Six Additional Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2020)... , ... February 23, 2020 ... ... has received a three-year accreditation by CARF International, the Commission on Accreditation ... and human services whose mission is to promote quality, value, and optimal ...
(Date:2/23/2020)... ... 23, 2020 , ... World-renowned actor Laurence Fishburne ( https://en.wikipedia.org/wiki/Laurence_Fishburne ... features a wide array of subjects impacting people all around the world today. ... discuss the importance of preventative dentistry and proper oral hygiene., Preventative dentistry is ...
(Date:2/21/2020)... ... , ... The business of healthcare management is complex. From providing the best ... patients digital and physical safety, there are many things to keep up with. Very ... is excited to provide their insights on healthcare facility maintenance to attendees at the ...
Breaking Medicine Technology:
(Date:2/21/2020)... ... February 21, 2020 , ... Representatives with ... a 10 percent grand opening discount 0n its anti-colic portable baby bottle blender. ... Osmay Gonzalez, spokesperson for Baby Blendy LLC, a member of the Juvenile Products ...
(Date:2/21/2020)... (PRWEB) , ... February 21, 2020 , ... ... to host the 2021 World Cancer Leaders’ Summit in Boston, MA, in October ... brings together key decision makers including prime ministers, ministers of health, city and ...
(Date:2/20/2020)... , ... February 20, 2020 , ... Millennial women are ... & Laser Center in Milford, Penn requesting treatments to achieve “ Rich Girl Face ... doesn’t look like it is slowing down into 2020. It’s a look inspired by ...
(Date:2/19/2020)... ... February 19, 2020 , ... The American College of Lifestyle ... Lifestyle Medicine Residency Curriculum (LMRC). The curriculum is the first comprehensive, applicable and ... Driven by resident involvement, the curriculum has included residents in every aspect of ...
(Date:2/19/2020)... ... February 19, 2020 , ... BPM+ Health , ... that it will participate in the HIMSS20 Global Health Conference & ... healthcare professionals and other stakeholders at HIMSS20 – the largest global health information ...
Breaking Medicine News(10 mins):